1. Neal A. Chatterjee et al. JCHF 2014;2:230-237
PH Subtype and Clinical Outcome Kaplan-Meier estimates of the probability of survival free of (A) the composite clinical outcome (death, heart transplantation, left ventricular assist device [LVAD] placement) or (B) all-cause mortality assessed at 2 years for patients without pulmonary hypertension (PH), PH with transpulmonary gradient (TPG) <12 mm Hg, and PH, TPG ≥12 mm Hg. Comparison testing of survival from clinical endpoints is shown for patients with PH, TPG ≥12 mm Hg versus those without PH and those with PH, TPG <12 mm Hg (log-rank p). There was no significant difference between patients with PH, TPG <12 mm Hg and patients without PH with respect to freedom from the composite outcome (log-rank p = 0.11) or all-cause mortality (log-rank p = 0.33).
Neal A. Chatterjee et al. JCHF 2014;2:
American College of Cardiology Foundation